SUPPLEMENT

Q1 2023 — Earnings infographic

Q1 2023PDF · 1 pages463 KB
Joaquin Duato
Chairman of the Board &
Chief Executive Officer
Johnson & Johnson
“Our first quarter results demonstrate strong
performance across all three segments of our
business and reflect the dedication of
Johnson & Johnson colleagues around the world.
With this momentum, I look forward to the
remainder of the year, one filled with exciting
catalysts that will create both near- and long-term
value for patients and all of our stakeholders.”
For full financial data and non-GAAP reconciliations, please refer to Johnson & Johnson’s earnings release issued on April 18, 2023 available at
http://www.investor.jnj.com/sales-earnings.cfm.
*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most
comparable GAAP financial measures.
**Basic shares are used to calculate loss per share as use of diluted shares when in a loss position would be anti-dilutive.
Non-GAAP measure; excludes the impact of translational currency.
Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation Reform
Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on
current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the
assumptions, expectations, and projections expressed in any forward-looking statements, review the “Note to Investors Concerning Forward-
Looking Statements” included in the Johnson & Johnson earnings release issued on April 18, 2023 as well as the most recently filed Johnson & Johnson
Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future
events or developments.
Increased Decreased 	
1st Quarter 2023 Results
1st Quarter 2023 Sales
Adjusted Diluted Earnings Per Share*
$2.68 0.4%
Basic Loss Per Share**
($0.03) (101.6)%
Worldwide
Increased 
$24.7B 	7.6%*
5.6%
Worldwide
Increased  	Excluding acquisitions/
divestitures on an
operational basis
Note: values may have been rounded.
$7.5MedTech worldwide reported sales increased 7.3% or 11.0%
operationally. Primary operational drivers:
 
Worldwide MedTech Sales
Billion
Wound Closure	Electrophysiology 	Contact Lenses
Hips	Biosurgery
Abiomed 	Knees
Energy 	Surgical Vision	Trauma
Billion
$13.4 Worldwide Pharmaceutical SalesPharmaceutical worldwide reported sales increased 4.2%
or 7.2% operationally. Primary operational drivers:
Consumer Health worldwide reported sales increased 7.4%
or 11.3% operationally. Primary operational drivers:
$3.9 	Worldwide Consumer Health Sales
Billion

-- 1 of 1 --